Stellantis introduced early Monday that it plans a second U.S. battery plant to assist assist American EV manufacturing.
With a memorandum of understanding signed between Stellantis and Samsung SDI Monday, the businesses search to start out manufacturing on the facility in 2027 and “an preliminary annual manufacturing capability of 34 gigawatt-hours.” However the location stays undisclosed and “at the moment below evaluation,” based on a launch.
The second battery plant will fall below the identical StarPlus Power three way partnership as its first U.S. facility at the moment being inbuilt Kokomo, Indiana and because of ramp up in early 2025.
Moreover, Stellantis reported that the Indiana plant will purpose for an annual manufacturing of 33 gigawatt-hours, up from 23 when the venture was introduced.
STLA Massive platform – Stellantis EVs
Stellantis’ different proposed battery plant, a three way partnership with LG Power Resolution, had been stalled till earlier this month over points by which “the Canadian authorities has not delivered on what was agreed to.”
As of July 5, the businesses reported the venture was again on, with the plant because of begin manufacturing in 2024, ramping as much as an annual output of greater than 45 gigawatt-hours.
That 4.5-million-square-foot manufacturing facility was beforehand because of be accomplished by the top of 2023. The positioning may even be serving as a expertise heart for cell, module, and battery-pack growth for EVs, hybrids, and plug-in hybrids, however the firm hasn’t but commented on how this delay would possibly have an effect on these plans.
Jeep Recon
Stellantis additionally hasn’t but supplied an replace on whether or not this impacts the timeline for the launch of upcoming EVs, probably together with the Ram 1500 REV electrical truck, a Dodge electrical muscle automotive, and a Jeep Recon that might act as a completely electrical “brother” to the Wrangler.
Samsung SDI cells have precedent in Stellantis’ U.S. EV lineup. The unique Fiat 500e that first arrived for restricted U.S. sale a decade in the past was geared up with cells from that firm.
